EGFR and neoplasm: The bsAb AFM24 developed by Affimed targets EGFR and CD16A located on innate immune cells and can bind and redirect innate immune cells such as NK cells and macrophages to EGFR+ tumor cells (134), thereby directly killing tumor cells.